Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin Placebo

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Aug 1, 2012 → Jul 1, 2014

About Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin Placebo

Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin Placebo is a phase 2 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT01675882. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01675882Phase 2Completed

Competing Products

20 competing products in Peanut Allergy

See all competitors